Q-omics provides the consensus-scored GALNT10 profile across patient tissues and cancer cell-line models. GALNT10 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, GALNT10 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, GALNT10 protein abundance shows 21,658 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCEC, HNSC, and LSCC as cancer lineages where GALNT10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GALNT10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GALNT10 survival associations across molecular data types. GALNT10 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GALNT10 RNA expression–survival associations across cancer types. High GALNT10 expression shows unfavorable associations in ACC, UVM, PAAD, LIHC and MESO, but favorable associations in UCEC. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for GALNT10 RNA expression.
This table summarizes GALNT10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GALNT10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GALNT10 shows lower tumor expression in THCA and LUSC and higher tumor expression in HNSC, LIHC, LUAD and BRCA. The HNSC box plot shows higher GALNT10 RNA expression in tumor versus normal tissue (log2 FC = +2.349, t-test p < 0.001).
This table shows molecular features associated with GALNT10 in patient tissues and cancer cell lines. In patient samples, GALNT10 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GALNT10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BONE.
